0001179110-17-010236.txt : 20170707 0001179110-17-010236.hdr.sgml : 20170707 20170707212952 ACCESSION NUMBER: 0001179110-17-010236 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170705 FILED AS OF DATE: 20170707 DATE AS OF CHANGE: 20170707 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nabriva Therapeutics Plc CENTRAL INDEX KEY: 0001703287 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 56 FITZWILLIAM SQUARE CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: 6108166640 MAIL ADDRESS: STREET 1: 1000 CONTINENTAL DRIVE STREET 2: SUITE 600 CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 FORMER COMPANY: FORMER CONFORMED NAME: Nabriva Plc DATE OF NAME CHANGE: 20170407 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HBM Healthcare Investments (Cayman) Ltd. CENTRAL INDEX KEY: 0001232258 STATE OF INCORPORATION: E9 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38132 FILM NUMBER: 17956221 BUSINESS ADDRESS: STREET 1: 2454 WEST BAY ROAD, 3RD FLOOR CITY: GRAND CAYMAN STATE: E9 ZIP: 00000 BUSINESS PHONE: 1 345 946 8002 MAIL ADDRESS: STREET 1: P.O BOX 30852 CITY: GRAND CAYMAN STATE: E9 ZIP: KY1-1204 FORMER NAME: FORMER CONFORMED NAME: HBM BIOVENTURES CAYMAN LTD DATE OF NAME CHANGE: 20030512 4 1 edgar.xml FORM 4 - X0306 4 2017-07-05 0 0001703287 Nabriva Therapeutics Plc NBRV 0001232258 HBM Healthcare Investments (Cayman) Ltd. GOVERNORS SQUARE, SUITE #4-212-2 23 LIME TREE BAY AVE., WEST BAY GRAND CAYMAN E9 00000 CAYMAN ISLANDS 0 0 1 0 Ordinary Shares 2017-07-05 4 S 0 2562 10.5232 D 2569315 D Ordinary Shares 2017-07-07 4 S 0 133 10.50 D 2569182 D On June 23, 2017, Nabriva Therapeutics plc ("Nabriva plc") became the successor of Nabriva Therapeutics AG ("Nabriva AG") pursuant to an exchange offer. Pursuant to the exchange offer, each outstanding common share of Nabriva AG was exchanged for ten ordinary shares of Nabriva plc and each outstanding American Depositary Share of Nabriva AG, which represented one-tenth of one common share of Nabriva AG, was exchanged for one ordinary share of Nabriva plc. On prior reports filed by the reporting person subsequent to the completion of the exchange offer, all references to American Depositary Shares of Nabriva AG should be understood to refer to ordinary shares of Nabriva plc.. The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions ranging from $10.50 to $10.74 Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. /s/ Jean-Marc Lesieur, Director 2017-07-07